肿瘤标志物CYFRA21-1测定对原发性肝癌的诊断价值

The value of tumor marker CYFRA21-1 detection in diagnosis of primary hepatic carcinoma

目的探讨肿瘤标志物CYFRA21-1测定对原发性肝癌的诊断价值。方法对原发性肝癌(PHC)组96例、肝良性疾病组52例(肝硬化组28例、乙肝、丙肝组24例)和正常对照组30例,检测血清CYFRA21-1水平并进行统计学分析。结果 PHC组血清CYFRA21-1水平明显高于肝良性疾病组和正常对照组,差异有统计学意义(P<0.01),肝良性疾病组和正常对照组血清CYFRA21-1水平比较差异也有统计学意义(P<0.01),但阳性检出率比较无统计学意义(P>0.05)。PHC组和肝良性疾病组血清CYFRA21-1阳性率分别为66.7%(64/96)、7.7%(4/52)。结论检测血清CYFRA21-1水平对原发性肝癌的监测和诊断有较高的价值。

Objective To study the value of tumor marker CYFRA21-1 detection in diagnosis of primary hepatic carcinoma.Methods Choosing three different groups, primary hepatic carcinoma group（96 cases）, benign hepatic disease（52 cases） including 28 cases of hepatic cirrhosis and 24 cases of hepatitis b or c, control group（30 cases）. Detecting serum level of CYFRA21-1 in the three groups, analyzing data by statistical methods. Results The serum level of CYFRA21-1 in primary hepatic carcinoma group is significantly higher than in benign hepatic disease group or control group（P0.05）. The positive rates of CYFRA21-1 detection in primary hepatic carcinoma group and benign hepatic disease are 66.7%（64/96） and 7.7%（4/52）. ConclusionDetection serum level of CYFRA21-1 has high value in detecting and diagnosing primary hepatic carcinoma.